Kamada Ltd. - Ordinary Shares (KMDA): Price and Financial Metrics
KMDA Stock Summary
- The ratio of debt to operating expenses for Kamada Ltd is higher than it is for about merely 16.65% of US stocks.
- KMDA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 12.16% of US stocks.
- Kamada Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -8.46%, greater than the shareholder yield of only 22.12% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Kamada Ltd, a group of peers worth examining would be OIIM, MOSY, KOPN, AWRE, and ADTN.
- Visit KMDA's SEC page to see the company's official filings. To visit the company's web site, go to www.kamada.com.
KMDA Stock Price Chart Interactive Chart >
KMDA Price/Volume Stats
|Current price||$6.17||52-week high||$13.33|
|Prev. close||$6.33||52-week low||$5.78|
|Day high||$6.32||Avg. volume||202,251|
|50-day MA||$6.43||Dividend yield||N/A|
|200-day MA||$7.54||Market Cap||274.69M|
Kamada Ltd. - Ordinary Shares (KMDA) Company Bio
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company was founded in 1990 and is based in Ness Ziona, Israel.
KMDA Price Forecast Based on DCF Valuation
|Current Price||DCF Fair Value Target:||Forecasted Gain:|
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Kamada Ltd. To summarize, we found that Kamada Ltd ranked in the 73th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 135.5% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Kamada Ltd, consider:
- The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately only 9.35% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than just 0% of stocks in its sector (Healthcare).
|Terminal Growth Rate in Free Cash Flow||Return Relative to Current Share Price|
KMDA Latest News Stream
|Loading, please wait...|
KMDA Latest Social Stream
View Full KMDA Social Stream
Latest KMDA News From Around the Web
Below are the latest news stories about Kamada Ltd that investors may wish to consider to help them evaluate KMDA as an investment opportunity.
Kamada ([[KMDA]] -0.3%) has announced an amendment to its license agreement with Takeda ([[TAK]] -3.0%) for Glassia, an intravenous FDA-approved therapy developed by the company for Alpha-1 Antitrypsin deficiency.The supplier of Glassia for Japanese pharma giant for distribution in territories including the U.S., Kamada is expected to transfer the Glassia manufacturing to...
Following the Completion of the Transition of GLASSIA Manufacturing, Kamada will Transfer the Product’s US Biologics License Application (BLA) to Takeda; Expected to Occur by End of 2021Kamada to Receive from Takeda a Payment of $2 Million for the BLA Transfer Final Sales-Based Milestone Payment of $5 Million Due to Kamada under the License Agreement was AcceleratedNo Other Material Changes to the GLASSIA License Agreement Between Kamada and TakedaKamada Continues to Distribute GLASSIA Outside of Takeda’s Territories and Invests in the Alpha-1 Antitrypsin Deficiency Field Through Continued Development of the Inhaled AAT Product, Currently in a Phase III Clinical Study REHOVOT, Israel, April 07, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharm...
Kamada Ltd (NASDAQ: KMDA) has announced top-line results from its Phase 1/2 trial in Israel evaluating plasma-derived hyperimmune globulin (IgG) treatment for COVID-19. Kamada had announced the interim results from the study in September last year. A total of 12 eligible patients were enrolled and received a single dose of 4 grams within three to 10 days of initial symptoms. The patients were followed for 84 days post-treatment. As previously reported, 11 of the 12 patients recovered following the treatment. Seven patients were discharged from the hospital at or before day five post-treatment, and the remaining four patients were discharged by day 9. Following the infusion of the product, anti-SARS CoV-2 IgG levels in the plasma of all patients increased. The effect of the treatment on ...
Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19)
As Previously Reported, 11 of the 12 Patients Recovered and were Discharged from Hospital; Seven Patients were Discharged at or Before Day 5 and the Remaining Four Patients were Discharged by Day 9 of TreatmentNo Infusion-Related Reactions or Adverse Events Considered Related to Study Drug were ObservedCompany Continues to Supply its IgG Product to Israeli Ministry of Health (IMOH) for Treatment of COVID-19 Patients in IsraelIMOH is Conducting a Multi-Center Clinical Study Comparing Kamada's Product to Convalescent Plasma in Hospitalized Patients Company is Ramping up Production of the Product in Anticipation of a Potential Expansion of the Supply to the IMOH and Possible Demand from Additional International Markets REHOVOT, Israel, March 31, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ...
Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S.
Transaction Furthers Kamada’s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company Kamada is Already Actively Engaged in the Expansion of the Center’s Collection Capacity; Planning to Open Additional Plasma Collection Centers REHOVOT, Israel, March 03, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today updated that it has completed the previously announced acquisition of the FDA licensed plasma collection center and certain related rights and assets from the privately-held Blood and Plasma Research, Inc (B&PR) of Beaumont, TX, USA. “This acquisition furthers our strategic goal of becoming a fully integrated specialty plasma company,” said Amir London, CEO of Kamada. “We are already actively enga...
KMDA Price Returns
Continue Researching KMDAWant to see what other sources are saying about Kamada Ltd's financials and stock price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!